How we treat metastatic colon cancer in older adults

Journal of Geriatric Oncology

Volumn 4, Issue 4, 2013, Pages 295-301

  Sanoff, Hanna K ^b   Goldberg, Richard M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Colon cancer; Elderly; Metastatic

Indexed keywords

5 FLUOROURACIL PLUS LEUCOVORIN; AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL PRODUCT; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MINOCYCLINE; OXALIPLATIN; PANITUMUMAB; REGORAFENIB; SUNSCREEN; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; ANTINEOPLASTIC ACTIVITY; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHEMOTHERAPY HOLIDAY; CONSERVATIVE TREATMENT; CYTOPENIA; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG INFUSION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; ELDERLY CARE; FRAIL ELDERLY; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HOSPICE CARE; HUMAN; INFUSION PUMP; INOPERABLE CANCER; INTESTINE OBSTRUCTION; LIVER CIRRHOSIS; LIVER FAILURE; LONGEVITY; MAINTENANCE CHEMOTHERAPY; METASTATIC COLORECTAL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; ONCOGENE K RAS; PATIENT COUNSELING; PATIENT DECISION MAKING; PATIENT PREFERENCE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RASH; REVIEW; RISK ASSESSMENT; STEREOTACTIC BODY RADIATION THERAPY; SURGICAL MORTALITY; SURGICAL RISK; THROMBOSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

CHEMOTHERAPY; COLON CANCER; ELDERLY; METASTATIC;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; PHENYLUREA COMPOUNDS; PROGNOSIS; PYRIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RISK FACTORS; VITAMIN B COMPLEX;

EID: 84884976399     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2013.07.007     Document Type: Review

References (56)

1. Howlader N., Noone A., Krapcho M., Neyman N., Aminou R., Waldron W., et al. SEER Cancer Statistics Review, 1975-2008 2011, National Cancer Institute, Bethesda, MD, [http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011].
2. Andre T., Boni C., Navarro M., Tabernero J., Hickish T., Topham C., et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol Jul 1 2009, 27(19):3109-3116. [PubMed PMID: 19451431. Epub 2009/05/20. eng].
3. Smith B.D., Smith G.L., Hurria A., Hortobagyi G.N., Buchholz T.A. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009, 27(17):2758-2765. [PubMed PMID: Medline:19403886. English].
4. Pal S.K., Katheria V., Hurria A. Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. CA Cancer J Clin Mar-Apr 2010, 60(2):120-132. [PubMed PMID: 20173172].
5. Extermann M., Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol May 10 2007, 25(14):1824-1831. [PubMed PMID: 17488980].
6. Tomlinson J.S., Jarnagin W.R., DeMatteo R.P., Fong Y., Kornprat P., Gonen M., et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol Oct 10 2007, 25(29):4575-4580. [PubMed PMID: 17925551].
7. Nordlinger B., Guiguet M., Vaillant J.C., Balladur P., Boudjema K., Bachellier P., et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer Apr 1 1996, 77(7):1254-1262. [PubMed PMID: 8608500].
8. Fong Y., Fortner J., Sun R.L., Brennan M.F., Blumgart L.H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg Sep 1999, 230(3):309-318. [discussion 18-21. PubMed PMID: 10493478. Pubmed Central PMCID: 1420876].
9. Scheele J., Stang R., Altendorf-Hofmann A., Paul M. Resection of colorectal liver metastases. World J Surg Jan-Feb 1995, 19(1):59-71. [PubMed PMID: 7740812].
10. Adam R., Frilling A., Elias D., Laurent C., Ramos E., Capussotti L., et al. Liver resection of colorectal metastases in elderly patients. Br J Surg Mar 2010, 97(3):366-376. [PubMed PMID: 20101645].
11. Nordlinger B., Sorbye H., Glimelius B., Poston G.J., Schlag P.M., Rougier P., et al. EORTC liver metastases intergroup randomized phase III study 40983: long-term survival results. J Clin Oncol 2012, 30. [Suppl. abstr 3508].
12. Nordlinger B., Sorbye H., Glimelius B., Poston G.J., Schlag P.M., Rougier P., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet Mar 22 2008, 371(9617):1007-1016. [PubMed PMID: 18358928].
13. Portier G., Elias D., Bouche O., Rougier P., Bosset J.F., Saric J., et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol Nov 1 2006, 24(31):4976-4982. [PubMed PMID: 17075115].
14. Mitry E., Fields A.L., Bleiberg H., Labianca R., Portier G., Tu D., et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol Oct 20 2008, 26(30):4906-4911. [PubMed PMID: 18794541].
15. Ychou M., Raoul J., Douillard J., Bugat R., Mineur L., Viret F., et al. A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). J Clin Oncol 2005, 23(16S):246s. [abstr 3502].
16. Van Cutsem E., Labianca R., Hossfeld D., Bodoky A., Roth A., Aranda E., et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). J Clin Oncol 2005, 23(16S):3s. [abstr 8].
17. Saltz L.B., Niedzwiecki D., Hollis D., Goldberg R.M., Hantel A., Thomas J.P., et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol Aug 10 2007, 25(23):3456-3461. [PubMed PMID: 17687149].
18. Allegra C.J., Yothers G., O'Connell M.J., Sharif S., Petrelli N.J., Colangelo L.H., et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol Jan 1 2011, 29(1):11-16. [PubMed PMID: 20940184. Pubmed Central PMCID: 3055856. Epub 2010/10/14. eng].
19. Ychou M., Hohenberger W., Thezenas S., Navarro M., Maurel J., Bokemeyer C., et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol Dec 2009, 20(12):1964-1970. [PubMed PMID: 19567451].
20. Alberts S.R., Sargent D.J., Nair S., Mahoney M.R., Mooney M., Thibodeau S.N., et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA Apr 4 2012, 307(13):1383-1393. [PubMed PMID: 22474202. Pubmed Central PMCID: 3442260].
21. Siperstein A.E., Berber E., Ballem N., Parikh R.T. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg Oct 2007, 246(4):559-565. [discussion 65-7. PubMed PMID: 17893492].
22. Hoyer M., Roed H., Traberg Hansen A., Ohlhuis L., Petersen J., Nellemann H., et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 2006, 45(7):823-830. [PubMed PMID: 16982546].
23. Koopman M., Antonini N.F., Douma J., Wals J., Honkoop A.H., Erdkamp F.L., et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet Jul 14 2007, 370(9582):135-142. [PubMed PMID: 17630036].
24. Seymour M.T., Maughan T.S., Ledermann J.A., Topham C., James R., Gwyther S.J., et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet Jul 14 2007, 370(9582):143-152. [PubMed PMID: 17630037].
25. Cunningham D., Lang I., Lorusso V., Ocvirk J., Shin D., Jonker D.J., et al. Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): results of a randomized international phase III trial (AVEX). J Clin Oncol 2013, 30(Suppl. 34). [abstr 337].
26. Tournigand C., Andre T., Achille E., Lledo G., Flesh M., Mery-Mignard D., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol Jan 15 2004, 22(2):229-237. [PubMed PMID: 14657227].
27. Saltz L.B., Clarke S., Diaz-Rubio E., Scheithauer W., Figer A., Wong R., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol Apr 20 2008, 26(12):2013-2019. [PubMed PMID: 18421054].
28. Van Cutsem E., Kohne C.H., Hitre E., Zaluski J., Chang Chien C.R., Makhson A., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med Apr 2 2009, 360(14):1408-1417. [PubMed PMID: 19339720. Epub 2009/04/03. eng].
29. Goldberg R.M., Sargent D.J., Morton R.F., Fuchs C.S., Ramanathan R.K., Williamson S.K., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol Jan 1 2004, 22(1):23-30. [PubMed PMID: 14665611].
30. Douillard J.Y., Siena S., Cassidy J., Tabernero J., Burkes R., Barugel M., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol Nov 1 2010, 28(31):4697-4705. [PubMed PMID: 20921465].
31. Loupakis F., Cremolini C., Masi G., Lonardi S., Zagonel V., Tenta P., et al. FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): results of the phase III randomized TRIBE trial. J Clin Oncol 2013, 30(Suppl. 34). [abstr 336].
32. Sargent D.J., Kohne C.H., Sanoff H.K., Bot B.M., Seymour M.T., de Gramont A., et al. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol Apr 20 2009, 27(12):1948-1955. [PubMed PMID: 19255311. Pubmed Central PMCID: 2669760].
33. Seymour M.T., Thompson L.C., Wasan H.S., Middleton G., Brewster A.E., Shepherd S.F., et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet May 21 2011, 377(9779):1749-1759. [PubMed PMID: 21570111. Pubmed Central PMCID: 3109515].
34. de Gramont A., Bosset J.F., Milan C., Rougier P., Bouche O., Etienne P.L., et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol Feb 1997, 15(2):808-815. [PubMed PMID: 9053508].
35. Hurwitz H.I., Fehrenbacher L., Hainsworth J.D., Heim W., Berlin J., Holmgren E., et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol May 20 2005, 23(15):3502-3508. [PubMed PMID: 15908660].
36. Kozloff M.F., Berlin J., Flynn P.J., Kabbinavar F., Ashby M., Dong W., et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology 2010, 78(5-6):329-339. [PubMed PMID: 20733336].
37. Bokemeyer C., Bondarenko I., Hartmann J.T., de Braud F., Schuch G., Zubel A., et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol Jul 2011, 22(7):1535-1546. [PubMed PMID: 21228335].
38. Maughan T.S., Adams R.A., Smith C.G., Meade A.M., Seymour M.T., Wilson R.H., et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Jun 18 2011, 377(9783):2103-2114. [PubMed PMID: 21641636. Pubmed Central PMCID: 3159415].
39. Tveit K.M., Guren T., Glimelius B., Pfeiffer P., Sorbye H., Pyrhonen S., et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol May 20 2012, 30(15):1755-1762. [PubMed PMID: 22473155].
40. Lacouture M.E., Mitchell E.P., Piperdi B., Pillai M.V., Shearer H., Iannotti N., et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol Mar 10 2010, 28(8):1351-1357. [PubMed PMID: 20142600].
41. Tournigand C., Cervantes A., Figer A., Lledo G., Flesch M., Buyse M., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol Jan 20 2006, 24(3):394-400. [PubMed PMID: 16421419].
42. Figer A., Perez-Staub N., Carola E., Tournigand C., Lledo G., Flesch M., et al. FOLFOX in patients aged between 76 and 80years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer Dec 15 2007, 110(12):2666-2671. [PubMed PMID: 17963264].
43. Chibaudel B., Maindrault-Goebel F., Lledo G., Mineur L., Andre T., Bennamoun M., et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol Dec 1 2009, 27(34):5727-5733. [PubMed PMID: 19786657].
44. TobotNcg Maughan Fluorouracil, oxaliplatin, CPT-11 use and sequencing in advanced colorectal cancer: the UK MRC FOCUS trial. GI Cancers Symposium 2005, 166. [abstr].
45. Rothenberg M.L., Oza A.M., Bigelow R.H., Berlin J.D., Marshall J.L., Ramanathan R.K., et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol Jun 1 2003, 21(11):2059-2069. [PubMed PMID: 12775730].
46. Bennouna J., Sastre J., Arnold D., Osterlund P., Greil R., Van Cutsem E., et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol Jan 2013, 14(1):29-37. [PubMed PMID: 23168366].
47. Grothey A., Sugrue M.M., Purdie D.M., Dong W., Sargent D., Hedrick E., et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol Nov 20 2008, 26(33):5326-5334. [PubMed PMID: 18854571].
48. Van Cutsem E., Peeters M., Siena S., Humblet Y., Hendlisz A., Neyns B., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol May 1 2007, 25(13):1658-1664. [PubMed PMID: 17470858].
49. Peeters M., Price T.J., Cervantes A., Sobrero A.F., Ducreux M., Hotko Y., et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol Nov 1 2010, 28(31):4706-4713. [PubMed PMID: 20921462].
50. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med Jul 22 2004, 351(4):337-345. [PubMed PMID: 15269313].
51. Jonker D.J., O'Callaghan C.J., Karapetis C.S., Zalcberg J.R., Tu D., Au H.J., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med Nov 15 2007, 357(20):2040-2048. [PubMed PMID: 18003960].
52. Sobrero A.F., Maurel J., Fehrenbacher L., Scheithauer W., Abubakr Y.A., Lutz M.P., et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol May 10 2008, 26(14):2311-2319. [PubMed PMID: 18390971].
53. Van Cutsem E., Tabernero J., Lakomy R., Prenen H., Prausova J., Macarulla T., et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol Oct 1 2012, 30(28):3499-3506. [PubMed PMID: 22949147].
54. Grothey A., Van Cutsem E., Sobrero A., Siena S., Falcone A., Ychou M., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Jan 26 2013, 381(9863):303-312. [PubMed PMID: 23177514].
55. Seymour M.T., Maughan T.S., Wasan H.S., Brewster A.E., Shepherd S.F., O'Mahoney M.S., et al. Capecitabine and oxaliplatin in elderly and/or frail patients with metastatic colorectal cancer: the FOCUS2 trial. J Clin Oncol 2007, 25(18S):500s. [abtract #9030].
56. Fuchs C.S., Moore M.R., Harker G., Villa L., Rinaldi D., Hecht J.R. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol Mar 1 2003, 21(5):807-814. [PubMed PMID: 12610178].